Details

Notice to stakeholders: Considerations regarding the proposed use of psilocybin mushrooms in clinical trials, or as a drug accessed through the Special Access Program (SAP) - Canada.ca

Metadata and links for an archived snapshot.

Source: Health Canada
Date: Jan 6, 2026 · edition #6
Timestamp: 2026-01-06T17:02:36.024Z
Language: en
Original URL: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/notice-considerations-proposed-use-psilocybin-mushrooms-clinical-trials-special-access-program.html?wbdisable=true
Replay URL: https://replay.healtharchive.ca/job-6/20260106170236/https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/notice-considerations-proposed-use-psilocybin-mushrooms-clinical-trials-special-access-program.html?wbdisable=true#ha_snapshot=481588
ID: 481588
Status: 200
Type: text/html

Independent archive · Not an official government website. For up-to-date recommendations, always consult the official source website.

Other snapshots